Long-term levels of protection of different types of immunity against the Omicron variant: a rapid literature review
Authors:
Open Access
- 1 May 2024
- journal article
- review article
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 154 (5) , 3732
Abstract
INTRODUCTION: With the emergence of newer SARS-CoV-2 variants and their substantial effects on the levels and duration of protection against infection, an understanding of these characteristics of the protection conferred by humoral and cellular immunity can aid in the proper development and implementation of vaccine and safety guidelines. METHODS: We conducted a rapid literature review and searched five electronic databases weekly from 1 November 2021 to 30 September 2022. Studies that assessed the humoral or cellular immunity conferred by infection, vaccination or a hybrid (combination of both) in adults and risk groups (immunocompromised and older populations) were identified. Studies were eligible when they reported data on immunological assays of COVID-19 (related to vaccination and/or infection) or the effectiveness of protection (related to the effectiveness of vaccination and/or infection). RESULTS: We screened 5103 studies and included 205 studies, of which 70 provided data on the duration of protection against SARS-CoV-2 infection. The duration of protection of adaptive immunity was greatly impacted by Omicron and its subvariants: levels of protection were low by 3–6 months from exposure to infection/vaccination. Although more durable, cellular immunity also showed signs of waning by 6 months. First and second mRNA vaccine booster doses increased the levels of protection against infection and severe disease from Omicron and its subvariants but continued to demonstrate a high degree of waning over time. CONCLUSION: All humoral immunities (infection-acquired, vaccine-acquired and hybrid) waned by 3–6 months. Cellular immunity was more durable but showed signs of waning by 6 months. Hybrid immunity had the highest magnitude of protection against SARS-CoV-2 infection. Boosting may be recommended as early as 3–4 months after the last dose, especially in risk groups.Keywords
This publication has 86 references indexed in Scilit:
- Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, CanadaJAMA Network Open, 2022
- Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 boosterJournal of Medical Virology, 2022
- Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron InfectionJAMA Network Open, 2022
- Durability of Heterologous and Homologous COVID-19 Vaccine BoostsJAMA Network Open, 2022
- Antibody titers after a third dose of the SARS‐CoV‐2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary?Journal of Medical Virology, 2022
- Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 VaccineJAMA Network Open, 2022
- Assessment of Antibody and T-Cell Responses to the SARS-CoV-2 Virus and Omicron Variant in Unvaccinated Individuals Recovered From COVID-19 Infection in Wuhan, ChinaJAMA Network Open, 2022
- mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include OmicronCell Reports, 2022
- Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong KongEBioMedicine, 2022
- Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With OcrelizumabJAMA Neurology, 2022